NORWALK, Conn., Oct. 9, 2025 /PRNewswire/ — Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology.
The partnership will combine Algen’s cutting-edge functional genomics and machine learning platform with AstraZeneca’s deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of next-generation medicines.
Harry Robb, Principal at Lifespan Vision Ventures, said “We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. This collaboration with AstraZeneca underscores the strength of Algen’s technology and its potential to transform drug discovery.”
As an early investor, Lifespan Vision Ventures is proud to support Algen Biotechnologies in its mission to advance transformative therapies that improve patient outcomes in age-related diseases and extend healthspan.
About Algen Biotechnologies
Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du as a spin-out from Nobel laureate Jennifer Doudna’s lab at UC Berkeley, Algen combines deep learning with high-throughput functional genomics to identify novel therapeutic targets. Its proprietary, end-to-end platform AlgenBrain™ integrates advanced computational models with scalable, single-cell experimental systems to decode causal disease biology and accelerate the development of next-generation therapies. Algen is headquartered in San Francisco, CA.
For more information, visit www.algenbio.com.
About Lifespan Vision Ventures
Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human vitality.
Contact: info@lifespanvision.com
Logo – https://mma.prnewswire.com/media/1780796/LifeSpan_Vision_Ventures_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lifespan-backed-algen-biotechnologies-partners-with-astrazeneca-to-advance-ai-drug-discovery-302579935.html
SecureTech formalizes U.S. “beachhead” strategy for its AI-driven construction subsidiary, targeting the rapidly growing Accessory…
PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management,…
NEW YORK, Dec. 11, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hong Kong's most iconic shopping mall, Harbour City…
11 December 2025 - The International Olympic Committee (IOC) today announced that it will extend its…
10 December 2025 - As anticipation builds across Italy and beyond, the Milano Cortina 2026 Organising Committee…